CY1123734T1 - Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου - Google Patents

Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου

Info

Publication number
CY1123734T1
CY1123734T1 CY20201101076T CY201101076T CY1123734T1 CY 1123734 T1 CY1123734 T1 CY 1123734T1 CY 20201101076 T CY20201101076 T CY 20201101076T CY 201101076 T CY201101076 T CY 201101076T CY 1123734 T1 CY1123734 T1 CY 1123734T1
Authority
CY
Cyprus
Prior art keywords
axon regeneration
nerve regeneration
complement
enhanced nerve
drugs used
Prior art date
Application number
CY20201101076T
Other languages
English (en)
Inventor
Frank Baas
Valeria Ramaglia
Original Assignee
Regenesance B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38857887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123734(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regenesance B.V. filed Critical Regenesance B.V.
Publication of CY1123734T1 publication Critical patent/CY1123734T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μεθόδους και φάρμακα που χρησιμοποιούνται για τη θεραπεία παθήσεων που απαιτούν αναγέννηση των αξόνων, π.χ. σε θηλαστικά που έχουν προσβληθεί από τραυματισμό ή ασθένεια του κεντρικού ή περιφερικού νευρικού συστήματος. Τα φάρμακα που χρησιμοποιούνται σε αυτές τις μεθόδους διευκολύνουν την αναγέννηση των αξόνων με την καταστολή του συστήματος συμπληρώματος. Συνθήκες που απαιτούν την αναγέννηση των αξόνων που μπορούν να αντιμετωπιστούν σύμφωνα με την εφεύρεση περιλαμβάνουν σωματικούς τραυματισμούς, καθώς και νευροεκφυλιστικές διαταραχές του περιφερειακού ή κεντρικού νευρικού συστήματος.
CY20201101076T 2006-10-10 2020-11-13 Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου CY1123734T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85027706P 2006-10-10 2006-10-10
EP07834628A EP2073898A1 (en) 2006-10-10 2007-10-10 Complement inhibition for improved nerve regeneration
PCT/NL2007/050490 WO2008044928A1 (en) 2006-10-10 2007-10-10 Complement inhibition for improved nerve regeneration
EP13181901.3A EP2698166B1 (en) 2006-10-10 2007-10-10 Complement inhibition for improved nerve regeneration

Publications (1)

Publication Number Publication Date
CY1123734T1 true CY1123734T1 (el) 2022-03-24

Family

ID=38857887

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101076T CY1123734T1 (el) 2006-10-10 2020-11-13 Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου

Country Status (16)

Country Link
US (4) US8703136B2 (el)
EP (4) EP2698166B1 (el)
JP (2) JP2010505946A (el)
AU (1) AU2007307375B2 (el)
CA (3) CA3154415A1 (el)
CY (1) CY1123734T1 (el)
DK (2) DK2698166T3 (el)
ES (2) ES2557056T3 (el)
HK (2) HK1194688A1 (el)
HU (2) HUE052964T2 (el)
LT (1) LT3028716T (el)
NZ (1) NZ576195A (el)
PL (2) PL2698166T3 (el)
PT (2) PT2698166E (el)
SI (2) SI2698166T1 (el)
WO (1) WO2008044928A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007307375B2 (en) 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
AU2014200822B2 (en) * 2006-10-10 2016-01-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
SI2320925T1 (sl) * 2008-07-10 2016-05-31 Regenesance B.V. Komplement antagonisti in njih uporaba
US9180160B2 (en) * 2008-08-20 2015-11-10 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury from intracerebral hemorrhage
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2013014092A1 (en) 2011-07-22 2013-01-31 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
EP2914291B1 (en) 2012-11-02 2022-02-23 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2964255T3 (da) 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
ES2750556T3 (es) 2014-06-12 2020-03-26 Ra Pharmaceuticals Inc Modulación de actividad del complemento
EP3233912B1 (en) 2014-12-19 2021-05-19 Regenesance B.V. Antibodies that bind human c6 and uses thereof
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
PT3685847T (pt) 2015-12-16 2023-03-14 Ra Pharmaceuticals Inc Moduladores de atividade de complemento
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
SI3468990T1 (sl) 2016-06-14 2024-07-31 Regeneron Pharmaceuticals, Inc. Protitelesa proti-C in njihove uporabe
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
MX2020005547A (es) 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
LT3893924T (lt) 2018-12-13 2024-10-10 argenx BV Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
WO2020219822A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
JP2023527693A (ja) 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド 神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
WO2021231204A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
JP2023527684A (ja) 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド 神経疾患を治療するための補体成分ｃ１ｓ阻害剤、並びにそれを使用する関連組成物、システム及び方法
WO2024081954A2 (en) 2022-10-14 2024-04-18 Sanegene Bio Usa Inc. Small interfering rna targeting c3 and uses thereof
WO2024137590A2 (en) 2022-12-19 2024-06-27 Sanegene Bio Usa Inc. Small interfering rna targeting cfb and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5177190A (en) 1989-01-03 1993-01-05 Merck & Co., Inc. Purified C5a receptor from human polymorphonuclear leukocytes
CA2071871A1 (en) 1989-10-27 1991-04-28 Eric Eldering C1 inhibitor muteins and uses thereof
GB9007971D0 (en) 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
ATE212859T1 (de) 1993-09-01 2002-02-15 Sanquin Bloedvoorziening C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JPH09510088A (ja) 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク 最終補体インヒビター融合遺伝子およびタンパク質
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
SE9503495L (sv) 1995-10-09 1997-04-10 Actinova Ltd Nytt protein
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5922690A (en) 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
ATE335511T1 (de) 1997-08-26 2006-09-15 Amgen Fremont Inc Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
WO1999021581A1 (en) 1997-10-28 1999-05-06 Steeves John D Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US20030096775A1 (en) 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
AU1915100A (en) * 1998-11-17 2000-06-05 Alkermes, Inc. A method of genetic vector delivery
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
WO2000065057A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
IL146196A0 (en) 1999-04-28 2002-07-25 Univ British Columbia Composition of neuronal regeneration comprising myelin specific antibodies and complement proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
US20060140939A1 (en) 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
JP2007500741A (ja) 2003-05-16 2007-01-18 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 一時的処置のための短い半減期を有するｃ１インヒビター
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005016285A2 (en) * 2003-08-13 2005-02-24 New York University Compositions and methods for inhibiting slit protein and glypican interactions
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
CA2561531C (en) 2004-02-10 2017-05-02 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
US20080113904A1 (en) 2004-03-26 2008-05-15 Trent Martin Woodruff Treatment of Neurological Conditions Using Complement C5a Receptor Modulators
US20090028850A1 (en) 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP1674580A1 (en) * 2004-12-23 2006-06-28 F. Hoffmann-La Roche Ag Method for identifying activators and/or inhibitors of enzyme activity
EP1863514A2 (en) 2005-04-01 2007-12-12 UMC Utrecht Holding B.V. Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
EP1738763A1 (en) * 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
JP2007008876A (ja) * 2005-06-30 2007-01-18 Avant Immunotherapeutics Inc 脊髄損傷を治療するための補体阻害タンパク質の使用
JP4753683B2 (ja) 2005-10-14 2011-08-24 オルテック インコーポレイテッド 細胞機能を変化させるための方法および組成物
ES2400306T3 (es) 2005-10-21 2013-04-09 Catalyst Biosciences, Inc. Proteasas modificadas que inhiben la activación del complemento
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
RS53864B1 (en) 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. EXTENDING ALOGRAPHIC SURVIVAL BY INHIBITING COMPLEMENT ACTIVITIES
EP2035585B1 (en) 2006-06-15 2014-01-01 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
AU2007307375B2 (en) 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
KR20100015773A (ko) 2007-03-22 2010-02-12 노파르티스 아게 Ｃ５ 항원 및 그의 용도
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
WO2008153962A2 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennylvania Method of reducing tissue loss in pancreatic islet cell transplantation
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
US20110092446A1 (en) 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009102488A2 (en) 2008-02-15 2009-08-20 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US10632170B2 (en) 2008-02-19 2020-04-28 The Trustees Of The University Of Pennsylvania Administration of compstatin to an individual for the treatment of a tumor
US20110293524A1 (en) 2008-02-29 2011-12-01 The Brigham and Women"s Hosptial Inc. Methods and compositions for the regulation of lectin complement pathway (lcp)-associated complement activation in hyperglycemic myocardial damage
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US9180160B2 (en) 2008-08-20 2015-11-10 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury from intracerebral hemorrhage
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
CA2738930C (en) 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110262456A1 (en) 2008-11-14 2011-10-27 Rekha Bansal Method of treating ischemia reperfusion injury
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
WO2011109338A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis

Also Published As

Publication number Publication date
CA2666466A1 (en) 2008-04-17
EP2698166B1 (en) 2015-09-30
NZ576195A (en) 2012-04-27
US8703136B2 (en) 2014-04-22
EP3804755A1 (en) 2021-04-14
HUE026042T2 (en) 2016-05-30
ES2831325T3 (es) 2021-06-08
EP2073898A1 (en) 2009-07-01
DK2698166T3 (en) 2015-12-21
CA2980614A1 (en) 2008-04-17
PL3028716T3 (pl) 2021-03-08
CA3154415A1 (en) 2008-04-17
JP2013189470A (ja) 2013-09-26
AU2007307375A1 (en) 2008-04-17
SI3028716T1 (sl) 2021-01-29
US20220227884A1 (en) 2022-07-21
PL2698166T3 (pl) 2016-03-31
JP2010505946A (ja) 2010-02-25
LT3028716T (lt) 2020-12-10
HUE052964T2 (hu) 2021-06-28
US20180022824A1 (en) 2018-01-25
CA2666466C (en) 2017-11-14
EP2698166A3 (en) 2014-04-02
WO2008044928A1 (en) 2008-04-17
PT3028716T (pt) 2020-11-23
EP2698166A2 (en) 2014-02-19
US20140255395A1 (en) 2014-09-11
DK3028716T3 (da) 2020-11-23
PT2698166E (pt) 2016-01-27
EP3028716B1 (en) 2020-09-16
EP3028716A1 (en) 2016-06-08
HK1194688A1 (zh) 2014-10-24
ES2557056T3 (es) 2016-01-21
SI2698166T1 (sl) 2016-02-29
HK1225620A1 (zh) 2017-09-15
AU2007307375B2 (en) 2013-11-28
US20100143344A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CY1123734T1 (el) Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου
EA201891152A1 (ru) Экстрацеллюлярные везикулы нервных клеток
WO2016210372A3 (en) Methods to treat neurological diseases
CY1118902T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
CY1115046T1 (el) Καινουργια sirnas και μεθοδοι χρησης αυτων
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112015022156A2 (pt) composições e métodos para modular a expressão de tau
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
EA201400969A1 (ru) Новые терапевтические подходы для лечения болезни паркинсона
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
DK2332408T3 (da) Behandling af neurologiske sygdomme
CL2019001512A1 (es) Tratamiento de enfermedades neurológicas.
WO2012040727A3 (en) Methods for diagnosis and treatment of neurodegenerative diseases or disorders
CY1118297T1 (el) Θεραπευτικες χρησεις της εσλικαρβαζεπινης